Lets break it down for you briefly
Supply shortages, insurance coverage changes, or cost differences between compounded semaglutide and affordable tirzepatide options can force people to switch between them out of necessity rather than strategy
In Quebec, where one in four adults is obese, the current cost of these new drugs (approximately $500 per month) would involve an annual expenditure of several hundred million dollars (in the United States the situation is even worse: the cost of a 72-week course of tirzepatide (15 mg/week) is approximately US$17,000, while the 68-week treatment with semaglutide (2.4 mg/week) is nearly US$23,000!)
Thats what youll see come back
A senior author reported serving on advisory boards and receiving grants from Eli Lilly and Novo Nordisk
The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90) (see Figure 2 and Table 6)